Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT01442792
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 108 participants
- Registry
-
NCT01442792 -
2011-001094-58
-
- Other papers using this trial's data
- Peri-procedural use of rivaroxaban in elective percutaneous coronary intervention to treat stable coronary artery disease. The X-PLORER trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01442792. Randomized; no masking; primary purpose prevention. Start 2011-10-12 (actual); primary completion 2013-01-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
- Acronym
- X-PLORER
- Condition
- Cardiovascular Disease
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- UFH
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939) and UFH
- Lead sponsor
- Bayer
- Collaborator
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01442792- Content hash
32508c09228e41b632ecc6241642b9caaaf83053b27942e34c7b879f9d1bf38a